Anaptysbio (ANAB) Cash from Investing Activities (2016 - 2026)

Anaptysbio's Cash from Investing Activities history runs 11 years deep, the most recent figure standing at $35.0 million for Q1 2026.

• Quarterly Cash from Investing Activities rose 135.62% year-over-year to $35.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $248.2 million (up 496.14% YoY) and the FY2025 annual result came in at $228.0 million, up 139.03% from the prior year.
• Cash from Investing Activities was $35.0 million for Q1 2026 at Anaptysbio, down from $73.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $103.3 million in Q3 2025 and bottomed at -$312.9 million in Q1 2022.
• A 5-year average of $6.4 million and a median of $30.6 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 651.59% — and 2025, when it surged 1590.7%.
• Anaptysbio's Cash from Investing Activities stood at $21.5 million in 2022, then jumped by 128.77% to $49.2 million in 2023, then sank by 159.77% to -$29.4 million in 2024, then soared by 350.03% to $73.5 million in 2025, then plunged by 52.4% to $35.0 million in 2026.
• Business Quant data shows ANAB's Cash from Investing Activities at $35.0 million in Q1 2026, $73.5 million in Q4 2025, and $103.3 million in Q3 2025.